Advertisement

Axogen, Inc. AXGN

Set alert

Price alert · AXGN

All alert types
49.37 USD -0.26 -0.52%

At close · Oct 30

50.35 +0.98 +1.99%

After hours · Oct 30, 6:44 PM ET

Bid
49.33 × 2
Ask
49.37 × 2
48.08 Day range 49.88
22.22 52-week range 51.73
YTD
+50.84%
1 year
+117.68%
Open
49.70
Prev close
49.63
Mkt cap
2.95B
Vol
1.84M
Avg vol
1.38M
EPS
-0.63
P/E
0.00
Div yield
0.00%
More statistics
Low
48.08
High
49.88
Forward P/E
69.55
Beta
1.17
Short ratio
3.57
Inst. own
95.98%
Dividend
0.00
Ex-div date
Jan 26, 2010
Earnings
Feb 23, 2027
50-d avg
42.80
200-d avg
39.48
1y target
57.73

2Y chart

Chart tools
Interval

Events in this range
  • Oct 29, 2025Earnings: 0.12; estimate 0.09; surprise 33.33%
  • Feb 24, 2026Earnings: 0.07; estimate 0.08879; surprise -21.16%
  • Apr 28, 2026Earnings: 0.07; estimate 0.12; surprise -41.67%
  • Jul 29, 2026Earnings: 0.12; estimate 0.1214; surprise -1.15%
  • Oct 28, 2026Earnings: 0.21; estimate 0.1313; surprise 59.94%
  • Oct 29, 2026Rating: HC Wainwright & Co. · Buy → Buy
  • Oct 29, 2026Rating: Wells Fargo · Overweight → Overweight
  • Oct 29, 2026Rating: Truist Securities · Buy → Buy
  • Oct 29, 2026Rating: Barclays · Overweight → Overweight
  • Oct 29, 2026Rating: Leerink Partners · Outperform → Outperform
  • Oct 29, 2026Rating: Canaccord Genuity · Buy → Buy
Signals (80)
NameDateAgo
SMA: BullishOct 28, 20264 days ago
SMA: BullishOct 28, 20264 days ago
RSI: OverboughtOct 28, 20264 days ago
MACD: Buy SignalOct 20, 20261 week ago
RSI: OversoldOct 13, 20262 weeks ago
SMA: BearishOct 2, 20261 month ago
RSI: OversoldOct 2, 20261 month ago
SMA: BearishSep 22, 20261 month ago
SMA: BullishSep 21, 20261 month ago
SMA: BearishSep 18, 20261 month ago
SMA: BullishSep 16, 20261 month ago
SMA: BearishSep 10, 20261 month ago
MACD: Sell SignalSep 1, 20262 months ago
RSI: OverboughtAug 12, 20262 months ago
SMA: BullishJul 31, 20263 months ago
MACD: Buy SignalJul 29, 20263 months ago
SMA: BearishJul 10, 20263 months ago
MACD: Sell SignalJul 7, 20263 months ago
MACD: Buy SignalJun 11, 20264 months ago
MACD: Sell SignalJun 10, 20264 months ago
MACD: Buy SignalJun 9, 20264 months ago
MACD: Sell SignalMay 11, 20265 months ago
RSI: OverboughtMay 5, 20266 months ago
RSI: OverboughtApr 30, 20266 months ago
RSI: OverboughtApr 28, 20266 months ago
SMA: BullishApr 13, 20266 months ago
SMA: BearishApr 10, 20266 months ago
SMA: BullishApr 8, 20266 months ago
SMA: BearishApr 6, 20266 months ago
SMA: BullishMar 31, 20267 months ago
SMA: BearishMar 26, 20267 months ago
SMA: BullishMar 24, 20267 months ago
SMA: BearishMar 18, 20267 months ago
SMA: BullishMar 16, 20267 months ago
MACD: Buy SignalMar 13, 20267 months ago
SMA: BearishFeb 24, 20268 months ago
MACD: Sell SignalFeb 24, 20268 months ago
MACD: Buy SignalFeb 23, 20268 months ago
MACD: Sell SignalFeb 9, 20268 months ago
MACD: Buy SignalJan 26, 20269 months ago
RSI: OverboughtDec 29, 202510 months ago
RSI: OverboughtDec 22, 202510 months ago
MACD: Sell SignalDec 11, 202510 months ago
MACD: Buy SignalNov 20, 202511 months ago
RSI: OverboughtNov 18, 202511 months ago
MACD: Sell SignalNov 17, 202511 months ago
RSI: OverboughtOct 29, 20251 year ago
MACD: Buy SignalOct 22, 20251 year ago
SMA: BullishOct 16, 20251 year ago
SMA: BearishOct 13, 20251 year ago
MACD: Sell SignalSep 25, 20251 year ago
MACD: Buy SignalSep 19, 20251 year ago
MACD: Sell SignalSep 2, 20251 year ago
SMA: BullishAug 26, 20251 year ago
SMA: BearishAug 25, 20251 year ago
RSI: OverboughtAug 13, 20251 year ago
RSI: OverboughtJul 23, 20251 year ago
SMA: BullishJul 10, 20251 year ago
RSI: OversoldJun 12, 20251 year ago
RSI: OversoldJun 9, 20251 year ago
MACD: Buy SignalMay 30, 20251 year ago
RSI: OversoldMay 28, 20251 year ago
RSI: OversoldMay 19, 20251 year ago
MACD: Sell SignalMay 8, 20251 year ago
RSI: OversoldMay 8, 20251 year ago
MACD: Buy SignalApr 25, 20251 year ago
MACD: Sell SignalApr 2, 20251 year ago
SMA: BearishApr 1, 20251 year ago
SMA: BullishMar 25, 20251 year ago
MACD: Buy SignalMar 25, 20251 year ago
SMA: BearishMar 18, 20251 year ago
SMA: BullishMar 17, 20251 year ago
SMA: BearishMar 6, 20251 year ago
MACD: Sell SignalMar 5, 20251 year ago
MACD: Buy SignalFeb 25, 20251 year ago
MACD: Sell SignalJan 27, 20251 year ago
MACD: Buy SignalJan 13, 20251 year ago
MACD: Sell SignalJan 6, 20251 year ago
RSI: OverboughtDec 23, 20241 year ago
MACD: Buy SignalDec 20, 20241 year ago

Key statistics

Market cap
2.95B
Enterprise value
2.64B
Trailing P/E
0.00
Forward P/E
69.55
PEG ratio
99.04
Price / sales
11.05
Price / book
5.94
EPS (TTM)
-0.63
Beta
1.17
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-11.96%
Revenue (TTM)
266.93M
Revenue growth
26.20%
Free cash flow
29.81M
Total cash
348.07M
Total debt
19.47M
Return on equity
-10.35%
Shares outstanding
59.73M
Short % of float
9.76%
50-day average
42.80
200-day average
39.48

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 57.73 +16.9% upside
Target (low)
48.00
Target (mean)
57.73
Target (high)
65.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy9
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Feb 23, 2027

Expected Feb 23, 2027. Consensus EPS estimate 0.15011.

Earnings history

Financials — quick view

All financials
AXGN Revenue — quarterly 75.83M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
AXGN Net income — quarterly 2.33M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
AXGN EPS — quarterly 0.04
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

AXGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20260.14———
Oct 28, 2026Sep 30, 20260.13130.21+0.08+59.94%
Jul 29, 2026Jun 30, 20260.12140.120.00-1.15%
Apr 28, 2026Mar 31, 20260.120.07-0.05-41.67%
Feb 24, 2026Dec 31, 20250.088790.07-0.02-21.16%
Oct 29, 2025Sep 30, 20250.090.12+0.03+33.33%

Upgrades / downgrades

AXGN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026Canaccord GenuitymainBuyBuy
Oct 29, 2026Leerink PartnersmainOutperformOutperform
Oct 29, 2026BarclaysmainOverweightOverweight
Oct 29, 2026Truist SecuritiesmainBuyBuy
Oct 29, 2026Wells FargomainOverweightOverweight
Oct 29, 2026HC Wainwright & Co.mainBuyBuy

About Axogen, Inc.

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on AXGN — it syncs with the Stock Master app.

Insider holders

AXGN insider holders
InsiderRelationLatest transactionDateShares held
BEGAN MARC A.General CounselConversion of Exercise of derivative securityFeb 26, 202650,135
DALE MICHAEL DChief Executive OfficerSaleDec 9, 202563,537
DEVINNEY ERICK WAYNEOfficerSaleMar 15, 2026262,781
HARTLEY LINDSEY MARIEChief Financial OfficerSaleMay 6, 202665,146
KEMP JENS SCHROEDEROfficerSaleMay 6, 202672,451
LEVINE ALAN M.DirectorConversion of Exercise of derivative securityJun 17, 202650,893

Institution ownership

AXGN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.40%4,419,208218.18MJun 29, 2026
Morgan Stanley4.60%2,747,924135.67MJun 29, 2026
First Light Asset Management, LLC4.60%2,748,361135.69MJun 29, 2026
Vanguard Capital Management LLC3.78%2,257,948111.47MJun 29, 2026
Artemis Investment Management Llp2.98%1,780,99287.93MSep 29, 2026
Polar Capital Holdings PLC2.51%1,500,82274.10MJun 29, 2026

Fund ownership

AXGN fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.67%1,596,14978.80MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.31%1,380,75668.17MSep 29, 2026
Manager Directed Portfolios-Hood River Small-Cap Growth Fund1.83%1,095,48254.08MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.02%609,72830.10MJun 29, 2026
T. Rowe Price New Horizons Fund, Inc.0.98%588,20029.04MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.96%575,48128.41MJul 30, 2026
Advertisement